GreenScreen HC
Gentronix has launched a new, accurate and fast in vitro mammalian cell genotoxicity assay - GreenScreen HC. The TK6 host cells are p53 competent and familiar to most genetic toxicology laboratories...
Gentronix Ltd.
Gentronix was founded in 1999 as a spin-out from The University of Manchester to commercialise patented new technology for the early identification of genotoxic carcinogens. This technology is now available in a kit format, known as GreenScreen HC, for the early genotoxicity screening of new drug compounds.
Developed in a simple microplate format requiring less than 1mg of compound, the assay is easily automated using standard laboratory equipment. Published results and trial data demonstrate a unique combination of exceptionally high sensitivity and specificity, making GreenScreen HC the first in vitro mammalian cell assay truly suitable for early candidate screening.
GreenScreen HC - S9 (Human Cells) and Metabolic Activation
In 2008 Gentronix launches a new S9 protocol to extend the application of the GreenScreen HC assay to include the detection of genotoxic metabolites. Many pharmaceuticals only present a genotoxicity...
BlueScreen HC: The luminescent adaptation of GreenScreen
BlueScreen HC is based on the fast, accurate GreenScreen HC genotoxicity assay from Gentronix Ltd. BlueScreen HC uses the same human-derived, p53-competent TK6 cells to host a patented reporter syst...
BlueScreen HC - S9
BlueScreen HC uses a single cell strain, which permits 8 compounds to be tested across 8 dilutions (2-fold serial), together with untreated and positive controls, in one 96-well microplate. After arra...
Predictive Toxicology Package
The cost of drug discovery continues to rise while the output of new NDAs continues to fall. Consequently it has never been more important to address attrition rates in drug discovery and development....
Browse Products by Field
Gentronix was founded in 1999 as a spin-out from The University of Manchester to commercialise patented new technology for the early identification of genotoxic carcinogens. This technology is now available in a kit format, known as GreenScreen HC, for the early genotoxicity screening of new drug compounds.
Developed in a simple microplate format requiring less than 1mg of compound, the assay is easily automated using standard laboratory equipment. Published results and trial data demonstrate a unique combination of exceptionally high sensitivity and specificity, making GreenScreen HC the first in vitro mammalian cell assay truly suitable for early candidate screening.